{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027314","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2026-08-12T20:10:36+00:00","discovered_at":"2026-08-12T20:12:29.393155+00:00","generated_at":"2026-08-12T20:12:38.035029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SeaStar Medical Q2 2026 revenue up 82% to $0.6M; net loss $3.7M; AKI trial 223/339","bullets":["Q2 net revenue $0.6M, up 82% vs $0.3M; gross margin 91% (vs 92%).","Net loss $3.7M ($0.91/share) vs $2.0M ($1.77/share) on higher R&D ($2.5M) and G&A ($1.8M).","Cash $7.0M at June 30, 2026, down from $12.0M at Dec 31, 2025.","NEUTRALIZE-AKI trial enrolled 223 of 339 adult AKI patients; completion expected year-end/Q1 2027.","CMS granted ICD-10-PCS codes for SCD therapy, effective Oct 1, 2026; added 3 children's hospitals (20 total)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027314","json":"https://secwatch.observer/filing/0001437749-26-027314.json","markdown":"https://secwatch.observer/filing/0001437749-26-027314.md","text":"https://secwatch.observer/filing/0001437749-26-027314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000143774926027314/0001437749-26-027314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000143774926027314/icu20260607_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:12:38.035029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}